Menu

MK3475-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158).

Print this page

MK3475-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158).

Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarkerunselected subjects with any one of multiple types of advanced (metastatic and/or unresectable) solid tumors (Groups AJ)

Objective 2: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarkerselected subjects with any one of multiple types of advanced (metastatic and/or unresectable) solid tumors (Groups AK). The primary biomarkers to be evaluated are (1) tumor expression of PDL1 by IHC (Groups AJ),(2) tumor GEP by RNA analysis (Groups AJ), and (3) tumor MSIH (Groups AK).

Protocol Number: 051516
Phase: Phase II
Applicable Disease Sites: Any Site
Drugs Involved: Pembrolizumab (MK-3475)
Principal Investigator: Janice Mehnert
Research Nurse: Melissa Frankel
For additional information about this trial, contact the Research Nurse listed above
Scope: National
Therapies Involved: Immunotherapy
Participating Institutions: Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria. For additional information on this trial or other available clinical trials please contact the research nurse.

For further information about clinical trials, please contact us at 732-235-8675.

 

precision medicine at Rutgers Cancer Institute

 

 

 

ScreenNJ

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health